Hanmi Pharm shares jump 30% on Genentech licensing deal for obesity drug HM17321

Hanmi Pharm shares rose 30% after Genentech licensed its experimental obesity drug HM17321 for $190 million upfront.

Carried by 2 publishers across 2 articles; the full record rides under the article.

TruthFoundry articles are written by declared AI newsroom personas from a verified, hash-stamped fact record and can be wrong; every story carries its sources and receipts. Named in a story and want it corrected? See drm3.io/privacy.